AU760466B2 - A novel inhibitor of programmed cell death - Google Patents

A novel inhibitor of programmed cell death Download PDF

Info

Publication number
AU760466B2
AU760466B2 AU33740/00A AU3374000A AU760466B2 AU 760466 B2 AU760466 B2 AU 760466B2 AU 33740/00 A AU33740/00 A AU 33740/00A AU 3374000 A AU3374000 A AU 3374000A AU 760466 B2 AU760466 B2 AU 760466B2
Authority
AU
Australia
Prior art keywords
aven
amino acid
sequence
vector
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33740/00A
Other languages
English (en)
Other versions
AU3374000A (en
Inventor
B. Nelson Chau
Emily H.-Y. Cheng
J. Marie Hardwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU3374000A publication Critical patent/AU3374000A/en
Application granted granted Critical
Publication of AU760466B2 publication Critical patent/AU760466B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
AU33740/00A 1999-02-26 2000-02-24 A novel inhibitor of programmed cell death Ceased AU760466B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12210499P 1999-02-26 1999-02-26
US60/122104 1999-02-26
PCT/US2000/004613 WO2000050453A1 (en) 1999-02-26 2000-02-24 A novel inhibitor of programmed cell death

Publications (2)

Publication Number Publication Date
AU3374000A AU3374000A (en) 2000-09-14
AU760466B2 true AU760466B2 (en) 2003-05-15

Family

ID=22400634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33740/00A Ceased AU760466B2 (en) 1999-02-26 2000-02-24 A novel inhibitor of programmed cell death

Country Status (7)

Country Link
US (1) US6570002B1 (enExample)
EP (1) EP1161444A4 (enExample)
JP (1) JP2002540769A (enExample)
AU (1) AU760466B2 (enExample)
CA (1) CA2363621A1 (enExample)
MX (1) MXPA01008626A (enExample)
WO (1) WO2000050453A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
JP4435563B2 (ja) * 2001-07-10 2010-03-17 バイオジェン アイデック インク アポトーシスプロセスの阻害および細胞性能の改善
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003901010A0 (en) * 2003-03-06 2003-03-20 Flinders Technologies Pty Ltd Apoptosis regulator
US7368428B2 (en) * 2003-06-23 2008-05-06 A&G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
ATE451924T1 (de) 2004-03-15 2010-01-15 Sunesis Pharmaceuticals Inc Sns-595 und anwendungsverfahren
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
JP2009545601A (ja) * 2006-08-02 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
US8518872B2 (en) * 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
CA2990477A1 (en) 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
DE69434614T2 (de) 1993-11-30 2006-10-05 Tanox, Inc., Houston Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5858715A (en) 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein

Also Published As

Publication number Publication date
MXPA01008626A (es) 2002-04-24
EP1161444A4 (en) 2005-11-02
AU3374000A (en) 2000-09-14
WO2000050453A1 (en) 2000-08-31
CA2363621A1 (en) 2000-08-31
US6570002B1 (en) 2003-05-27
JP2002540769A (ja) 2002-12-03
EP1161444A1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
US6570002B1 (en) Inhibitor of programmed cell death
JP2002524039A (ja) ヒトアポプトシス阻害剤タンパク質ｈｉａｐ３をコードするｄｎａ
US6472508B1 (en) Human tumor suppressor
US5763220A (en) Human apoptosis-related calcium-binding protein
US6773911B1 (en) Apoptosis-inducing factor
CA2279260A1 (en) Human apoptosis-associated protein; encoding dna is similar to p53 response mouse gene ei124
WO1998025956A2 (en) Human gtp-binding proteins
US6010859A (en) RAB protein
CA2332307A1 (en) Human transport protein homologs
US5861495A (en) Human zinc binding proteins
US5847093A (en) Human apoptosis regulator
WO1998029448A1 (en) Human pathogenesis-related protein
US20020034777A1 (en) Novel regulator of cell signaling
US6432915B1 (en) Human mitochondrial chaperone protein
US6280733B1 (en) Microtubule-associated protein
US6204372B1 (en) DNA encoding a human tubby homolog
CA2340617A1 (en) Genes associated with neurotransmitter processing
JP2005502305A (ja) 細胞増殖、細胞分化および細胞死に関連するタンパク質
US6995241B1 (en) Splice variant of head trauma induced cytoplasmatic calcium binding protein
US20040143111A1 (en) Novel apoptosis-associated protein
CA2322381A1 (en) Human synapse related glycoproteins (hsrp)
CA2321667A1 (en) Human channel-related molecules
US20020155553A1 (en) Human vesicle binding protein
US20040248829A1 (en) Functions for d52 and ra006 nucleic acids and polypeptides
WO1998050425A2 (en) Human tsc-22-like proteins